PALB2 and cancer: Heterozygous germline variants in PALB2 significantly increase the risk for various cancers, including breast (22–32), ovarian (22, 24, 28, 31), pancreatic (22, 24, 30, 33), prostate (22, 34), colorectal (35) cancer, and so forth, with a significant decrease in these patients’ survival (34).